X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) and Curis (NASDAQ:CRIS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
Earnings and Valuation
This table compares X4 Pharmaceuticals and Curis”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| X4 Pharmaceuticals | $1.12 million | 69.22 | -$101.17 million | ($0.09) | -5.06 |
| Curis | $10.02 million | 2.70 | -$47.41 million | ($7.81) | -0.41 |
Curis has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Analyst Ratings
This is a summary of current ratings and target prices for X4 Pharmaceuticals and Curis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| X4 Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Curis | 0 | 0 | 3 | 0 | 3.00 |
X4 Pharmaceuticals currently has a consensus price target of $3.50, indicating a potential upside of 667.88%. Curis has a consensus price target of $23.00, indicating a potential upside of 621.00%. Given X4 Pharmaceuticals’ higher possible upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than Curis.
Insider and Institutional Ownership
72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares X4 Pharmaceuticals and Curis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| X4 Pharmaceuticals | N/A | -236.19% | -75.14% |
| Curis | -443.35% | -923.37% | -78.35% |
Summary
X4 Pharmaceuticals beats Curis on 7 of the 11 factors compared between the two stocks.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
About Curis
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
